Inflammation as a Marker of Clinical Response to Treatment: A Focus on Treatment-Resistant Depression

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

8 Citations (Scopus)


Approximately one-third of those with major depressive disorder (MDD) develop treatment-resistant depression (TRD), and this is an important subpopulation in which there are clear unmet treatment needs. The ability to identify individuals who are more likely to manifest treatment nonresponse a priori would facilitate early, optimized care tailored to patients. Some research suggests that elevated inflammation predicts a poor response to antidepressants; indeed, it has been proposed that an “inflammatory subtype” of MDD may characterize a proportion of patients with TRD. This has yet to be firmly established, but there are many parallels between treatment resistance and inflammatory hyperactivity including obesity, metabolic symptoms, physical illness, cognitive deficits, and a history of early-life stress. The influence of medication on inflammatory activity is also unclear at this stage. If predictors of response in TRD are identified, improved and targeted care might be more reliably provided to this vulnerable population.
Original languageEnglish
Title of host publicationInflammation and Immunity in Depression
Subtitle of host publicationBasic Science and Clinical Applications
EditorsBernhard T Baune
Number of pages14
ISBN (Electronic)9780128110744
ISBN (Print)9780128110737
Publication statusPublished - 6 Jun 2018


  • Treatment-resistant depression
  • Treatment response
  • Remission
  • Inflammation
  • Subtypes


Dive into the research topics of 'Inflammation as a Marker of Clinical Response to Treatment: A Focus on Treatment-Resistant Depression'. Together they form a unique fingerprint.

Cite this